Fig. 5: SNVs and CNAs in recurrently mutated breast cancer genes. | Nature Cancer

Fig. 5: SNVs and CNAs in recurrently mutated breast cancer genes.

From: Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

Fig. 5

a, Oncoplot depicting predicted driver SNVs (top) and CNAs (bottom) for 53 participants in genes previously described as recurrent or associated with antiestrogen resistance in ER+ breast cancer. For SNVs, in cases where participants had multiple driver mutations in a single gene, only the ‘most serious’ consequence is plotted. Samples are ordered by EOT Ki67. Right, bar plots showing the frequency of aberrations in the indicated genes across the whole cohort. b,c, Box plots of genome-wide TMB (log2 transformed) in good (n = 41) versus poor responders (n = 12) (defined as EOT Ki67 ≥ 10%) (b) and log-transformed EOT Ki67 values in tumors with FGFR1 amplification (n = 9) versus nonamplified tumors (n = 44) (c). Data points are colored according to response (poor response: EOT Ki67 ≥ 10%). Statistical analysis was conducted using two-sided t-tests. Box, IQR; center, median; whiskers, min–max (excluding outliers, defined as <Q1 − 1.5 × IQR or >Q3 + 1.5 × IQR).

Source data

Back to article page